BRPI0923422A2 - promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor " - Google Patents

promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor "

Info

Publication number
BRPI0923422A2
BRPI0923422A2 BRPI0923422A BRPI0923422A BRPI0923422A2 BR PI0923422 A2 BRPI0923422 A2 BR PI0923422A2 BR PI0923422 A BRPI0923422 A BR PI0923422A BR PI0923422 A BRPI0923422 A BR PI0923422A BR PI0923422 A2 BRPI0923422 A2 BR PI0923422A2
Authority
BR
Brazil
Prior art keywords
infections
graft
versus
maintains
prophylactic agent
Prior art date
Application number
BRPI0923422A
Other languages
English (en)
Inventor
Matsushima Kouji
Shono Yusuke
Ueha Satoshi
Original Assignee
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo filed Critical Univ Tokyo
Publication of BRPI0923422A2 publication Critical patent/BRPI0923422A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0923422A 2008-12-12 2009-11-04 promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor " BRPI0923422A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008316828 2008-12-12
PCT/JP2009/068805 WO2010067671A1 (ja) 2008-12-12 2009-11-04 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤

Publications (1)

Publication Number Publication Date
BRPI0923422A2 true BRPI0923422A2 (pt) 2016-06-21

Family

ID=42242663

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923422A BRPI0923422A2 (pt) 2008-12-12 2009-11-04 promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor "

Country Status (5)

Country Link
US (1) US9156912B2 (pt)
JP (1) JP5688734B2 (pt)
CN (1) CN102271711B (pt)
BR (1) BRPI0923422A2 (pt)
WO (1) WO2010067671A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471543A1 (en) * 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
MX2014010209A (es) * 2012-02-29 2014-11-21 Toray Industries Agente inhibidor para acumulacion de fluido de la cavidad corporal.
EP2934589B1 (en) * 2012-12-18 2021-01-13 The Rockefeller University Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
WO2015125652A1 (ja) * 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
ES2818800T3 (es) * 2014-06-11 2021-04-14 Idac Theranostics Inc Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario
US11499168B2 (en) 2016-04-25 2022-11-15 Universitat Basel Allele editing and applications thereof
LT3535392T (lt) * 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
CN110913873A (zh) * 2017-02-23 2020-03-24 希望之城 用于cd8+t细胞的体内扩增并预防或治疗gvhd的方法
EP4417210A1 (en) 2017-03-15 2024-08-21 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
CN114832014B (zh) * 2022-07-04 2022-10-21 北京大学人民医院 Nk细胞的应用、nk细胞回输制剂以及组合制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653684B2 (ja) * 1987-12-02 1994-07-20 ベクトン・ディッキンソン・アンド・カンパニー 移植片対宿主病を防ぐための薬剤キット
US5178858A (en) 1987-12-02 1993-01-12 Reichert Thomas A Method for prevention of graft versus host disease
US6911220B1 (en) * 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
EP1224261A1 (en) 1999-10-07 2002-07-24 Avi Biopharma, Inc. C-myc antisense-treated hematopoietic stem cell composition and method
JP2003246751A (ja) * 2002-02-22 2003-09-02 Sumitomo Pharmaceut Co Ltd 骨髄移植後合併症治療剤
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells

Also Published As

Publication number Publication date
JP5688734B2 (ja) 2015-03-25
US20120027748A1 (en) 2012-02-02
WO2010067671A1 (ja) 2010-06-17
US9156912B2 (en) 2015-10-13
CN102271711B (zh) 2014-06-18
CN102271711A (zh) 2011-12-07
JPWO2010067671A1 (ja) 2012-05-17

Similar Documents

Publication Publication Date Title
BRPI0923422A2 (pt) promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor "
GB2467685B (en) Risk scoring system for the prevention of malware
IL236054A0 (en) Compositions and methods for treating Crohn's disease and related conditions and infections
IL213489A0 (en) Compositions and methods for the treatment of the prevention of e. coli infections and for the eradication or reduction of e. coli surfaces
BRPI0822625A2 (pt) "dispositivo espaçador modular para o tratamento de infecções por próteses"
NO20091183L (no) Derivater av 4-(N-azacykloalkyl)-anilider, fremgangsmåte for fremstilling av slike forbindelser, preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for forhindring eller behandling av sykdom
PT2898885T (pt) Derivados de pirrolopirimidina para utilização no tratamento de infeções virais
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
IL213528A0 (en) Compositions and methods for the treatment of the prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
BRPI1013642A2 (pt) derivado de triazina e composição farmacêutica compreendendo o mesmo
FR23C1002I1 (fr) 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse
EP2479216A4 (en) EMULSION AND MOLDING SOLVENT WITH THE EMULSION
BRPI1016257A2 (pt) composições compreendendo finafloxacino e métodos para tratar infecções oftálmicas, ópticas ou nasais
BRPI0923567A2 (pt) agentes antibactericidas novos para o tratamento de infecções gram positivas
SMT201600190B (it) Uso di streptococcus salivarius nel trattamento di infezioni croniche dell'apparato respiratorio
EP2872155A4 (en) BIOMATERIALS FOR IMPROVED IMPLANT HOST INTEGRATION
BR112014009456A2 (pt) uso de melatonina para o tratamento e/ou prevenção de mucosite
CL2014003607A1 (es) Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer.
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
IL197783A0 (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
ITMI20080195A1 (it) Procedimento per la preparazione di solifenacin
EP2604607A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS
EP2249843A4 (en) USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF INFECTIONS BY DISEASES
EP2484379A4 (en) MEDIUM FOR THE PREVENTION OF ARTERIOSCLEROSIS

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 3A ANUIDADE.

B08H Application fees: decision cancelled

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2385 DE 20/09/2016.

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 9A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2486 DE 28/08/2018.